Anti-EBV Latent Membrane Protein 1 [S12] Antibody

This mouse IgG2a monoclonal antibody recognizes Epstein-Barr virus (EBV). This antibody has been shown to be superior to common, CS1-4 cocktail-based antibodies.

Highlights:

  • Superior to CS1-4 cocktail-based antibodies
  • Generated against the C-terminus of Latent Membrane Protein 1 (LMP1)
  • Recommended for Western Blot, Immunoprecipitation, Immunofluorescence, and Immunohistochemistry applications

Latent Membrane Protein 1 (LMP1) is the dominant oncogene expressed by Epstein-Barr virus (EBV). It is expressed in the plasma membrane of transformed B cells latently infected with the virus. It is essential transformation by EBV. It is found in EBV positive tumors including immunoblastic and Hodgkin’s lymphoma and nasopharyngeal carcinomas.

From the laboratory of David Thorley-Lawson, PhD, Tufts University.

Catalog Number Product DataSheet Size AVAILABILITY Price Qty
ETU001
Anti-EBV Latent Membrane Protein 1 [S12] Antibody
100ug In stock
Regular Price:$364.00
On Sale:
Specifications

Product Type: Antibody
Antigen: Epstein-Barr virus latent membrane protein 1 (LMP1)
Molecular Weight: 63 kDa
Isotype: IgG2a
Clonality: Monoclonal
Clone Name: S12
Reactivity: Epstein-Barr virus
Immunogen: C-terminal 189 amino acids fused to beta-galactosidase
Species Immunized: Mouse
Purification Method: Protein G column
Buffer: 0.1M Sodium Phosphate, pH 7.4, 0.15M NaCl, 0.05% (w/v) Sodium Azide
Tested Applications: WB, IF, IH, IP
Storage: -20C
Shipped: Cold packs

Data

Western Blot Analysis

Western blots were performed with the S12 monoclonal antibody. The following subcellular fractions of the cell line BH were tested for the presence of LMP1: plasma membranes (lane B), cytoplasm (lane C), endoplasmic reticulum (lane D), mitochondria (lane F), and nucleus (lane G). In lanes B and D, 25ug samples of protein were used, and in lanes C, F, and G, 50ug samples were used. Lanes A and E contain 14C-labeled molecular weight standards and no material, respectively.

Adapted from: Mann KP, et al. J Virol. 1985 Sep;55(3):710-20.

Immunofluorescence Analysis

Immunofluorescence on EBV-positive and -negative cell lines. Immunofluorescence was performed with the S12 monoclonal antibody upon the methanol-fixed cell lines BH (A) and RAMOS (B).

Adapted from: Mann KP, et al. J Virol. 1985 Sep;55(3):710-20.

Provider
From the laboratory of David Thorley-Lawson, PhD, Tufts University.
References
  1. Mann KP, Staunton D, Thorley-Lawson DA. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol. 1985 Sep;55(3):710-20.
  2. Lew QJ, Chu KL, Chia YL, Soo B, Ho JP, Ng CH, Kwok HS, Chiang CM, Chang Y, Chao SH. GCN5 inhibits XBP-1S-mediated transcription by antagonizing PCAF action. Oncotarget. 2015 Jan 1;6(1):271-87. View Article
  3. Khabir A, Karray H, Rodriguez S, Rosé M, Daoud J, Frikha M, Boudawara T, Middeldorp J, Jlidi R, Busson P. EBV latent membrane protein 1 abundance correlates with patient age but not with metastatic behavior in north African nasopharyngeal carcinomas. Virol J. 2005 Apr 20;2:39
  4. Xu J, Ahmad A, Menezes J. Preferential localization of the Epstein-Barr virus (EBV) oncoprotein LMP-1 to nuclei in human T cells: implications for its role in the development of EBV genome-positive T-cell lymphomas. J Virol. 2002 Apr;76(8):4080-6.
  5. Gondhowiardjo S. Epstein-Barr virus latent membrane protein 1 (EBV-LMP1) and tumor proliferation rate as predictive factors of nasopharyngeal cancer (NPC) radiation response. Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:323-31.
  6. Brink AA, Dukers DF, van den Brule AJ, Oudejans JJ, Middeldorp JM, Meijer CJ, Jiwa M. Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. J Clin Pathol. 1997 Nov;50(11):911-8.
  7. Jiwa NM, Oudejans JJ, Dukers DF, Vos W, Horstman A, van der Valk P, Middledorp JM, Walboomers JM, Meijer CJ. Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases. J Clin Pathol. 1995 May;48(5):438-42.
  8. Chen ML, Hsu NC, Liu ST, Chang YS. Identification of an internal promoter of the latent membrane protein 1 gene of Epstein-Barr virus. DNA Cell Biol. 1995 Mar;14(3):205-11. J Gen Virol. 1988 May;69 ( Pt 5):1051-65.
  9. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T, Johnson A, Rickinson AB. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol. 1988 May;69 ( Pt 5):1051-65.
  10. Tempera I, De Leo A, Kossenkov AV, Cesaroni M, Song H, Dawany N, Showe L, Lu F, Wikramasinghe P, Lieberman PM. Identification of MEF2B, EBF1, and IL6R as Direct Gene Targets of Epstein-Barr Virus (EBV) Nuclear Antigen 1 Critical for EBV-Infected B-Lymphocyte Survival. J Virol. 2015 Oct 14;90(1):345-55. doi: 10.1128/JVI.02318-15. PubMed PMID: 26468528; PubMed Central PMCID: PMC4702570. View Article
  11. Wille CK, Li Y, Rui L, Johannsen EC, Kenney SC. Restricted TET2 Expression in Germinal Center Type B Cells Promotes Stringent Epstein-Barr Virus Latency. J Virol. 2017 Feb 14;91(5). pii: e01987-16. View Article

If you publish research with this product, please let us know so we can cite your paper.

Loading...